Subcutaneous Rybrevant Approved by European Commission for Every-Three-Week and Every-Four-Week Dosing for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
February 24, 2026
February 24, 2026
RARITAN, New Jersey, Feb. 24 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 23, 2026:
* * *
Subcutaneous RYBREVANT(R) (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantama . . .
* * *
Subcutaneous RYBREVANT(R) (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantama . . .